-+ 0.00%
-+ 0.00%
-+ 0.00%

Egetis says tiratricol wins Japan orphan drug designation for MCT8 deficiency

PUBT·08/31/2026 06:07:24
Listen to the news
Egetis says tiratricol wins Japan orphan drug designation for MCT8 deficiency
  • Japan’s MHLW granted orphan drug designation for tiratricol to treat MCT8 deficiency under Egetis partner Fujimoto Pharmaceutical.
  • Status enables priority review for a future marketing application, cutting review time to about nine months from 12 months.
  • Market exclusivity would extend to 10 years if approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.